Hansa Biopharma GAAP EPS of -SEK1.75, revenue of SEK 30.8M
Source: SeekingAlpha
2025-10-30 08:45:01 ET
More on Hansa Biopharma
- Hansa Biopharma AB (publ) Discusses on ConfIdeS US Phase 3 Pivotal Trial Topline Results Presentation
- Hansa Biopharma AB (Publ) Discusses On ConfIdeS US Phase 3 Pivotal Trial Topline Results Call (Transcript)
- Seeking Alpha’s Quant Rating on Hansa Biopharma
- Historical earnings data for Hansa Biopharma
- Financial information for Hansa Biopharma
Read the full article on Seeking Alpha
For further details see:
Hansa Biopharma GAAP EPS of -SEK1.75, revenue of SEK 30.8M
Hansa Biopharma AB
NASDAQ: HNSBF
HNSBF Trading
-85.0% G/L:
$2.91 Last:
28,750 Volume:
$2.91 Open:
HNSBF Latest News
September 24, 2025 02:06:00 pm
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
